Literature DB >> 16254803

Challenges and opportunities for positron-emission tomography in personalized medicine.

Suzanne V Smith1.   

Abstract

Of the non-invasive functional imaging tools available, positron-emission tomography (PET) is generally expected to have the greatest potential for delivering the vision of personalized medicine. This can be achieved by the production of designer PET probes with exquisite sensitivity that can profile key biological processes that are specific to a disease. However, the challenge for the PET field will be its capability to produce and supply cost-effective PET probes to the wider community. This will most likely be achieved through the provision of long-lived PET radioisotopes with imaging qualities that match the performance of the evolving PET camera technology and chemistry that is amenable to kit formulations. Additionally, of the emerging PET radiotracers, (64)Cu has the optimum chemistry and emission characteristics for the wider application of PET in personalized medicine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254803

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  3 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

3.  Imaging of hepatic drug transporters with [131I]6-β-iodomethyl-19-norcholesterol.

Authors:  Masato Kobayashi; Kodai Nishi; Asuka Mizutani; Tsuzumi Hokama; Miki Matsue; Tetsuya Tsujikawa; Takeo Nakanishi; Ryuichi Nishii; Ikumi Tamai; Keiichi Kawai
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.